Pack shot Krka Robexera
New Robexera® From Krka Targets Pain From Osteoarthritis And Soft Tissue Surgery In Dogs
5 months ago 
722 views
Krka has announced the launch of Robexera®, a fast-acting solution for the treatment of pain and inflammation associated with chronic osteoarthritis (OA) and soft tissue surgery in dogs.¹
Robexera (robenacoxib) is a highly selective, fast-acting COX2 NSAID formulation that delivers targeted anti-inflammatory pain relief with reduced systemic impact. Robenacoxib’s ability to persist at the site of inflammation enables Robexera to provide effective 24-hour pain relief on a simple, once-a-day dosing regime²³⁴. The product is presented as a flavoured chewable tablet for easier administration by pet owners. For simplicity when dispensing, it comes in four strengths with colour coded boxes, perforated blisters and a set of PIL sheets that convert to prescribing envelopes in each pack.
Commenting, Charlotte Read, Krka’s UK Key Account Manager, says: “Delivering reliable, cost-effective perioperative pain relief for soft tissue surgery is an everyday concern for veterinary practices, while OA is the most common cause of chronic pain in dogs5. This is why we’re particularly pleased to announce the first generic robenacoxib, Robexera.
“Bioequivalent to the originator product6, Robexera provides fast-acting and targeted pain relief, giving enhanced value to veterinary practices and enabling them to offer their clients improved affordability, particularly for those whose animals are on long term pain-management programmes or have other health issues.”
Viktor Kozjan, General Manager Krka UK, added: “The launch of Robexera is further confirmation of Krka’s commitment to develop solutions that are tried and trusted but also flexible and affordable for our customers and their clients.”
Robexera is now available to order from all national UK veterinary wholesalers.
The Krka Team will be attending London Vet Show to discuss Robexera and the wider range of animal health solutions now offered for UK veterinary practice customers (stand S45).
Krka is one of the leading generic pharmaceutical companies in the world, and our medicines are used to treat more than 50 million human and animal patients worldwide every day. With over 50 years in developing animal health solutions Krka continues to bring innovation to the category with its branded generics.
Working closely with customers, Krka supplies licensed medicines that deliver effective and consistent performance in clinical practice. Krka’s Animal Health Portfolio provides high efficacy pharmaceuticals for both companion and food producing animals covering parasite control, infection management and pain relief. Key brands for companion animals include Milprazon CHEWABLE® and Prinocate®, for parasite management and Cladaxxa® for infection control.
References
¹ Product Information Database (defra.gov.uk)
² Silber HE, et al.(2010) Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis. Pharm Res 27:2633-2645. doi: 10.1007/s11095-010-0262z .
³Kongara K. , Chambers J.C. (2018) “Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy and place in therapy.” Veterinary medicine (Auckland, N.Z.) vol. 9 53-61. 15 Aug.2018, doi:10.2147/VMRR.S170893
⁴Lees, P., et al. (2022). Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 45, 325–351. https://doi.org/10.1111/jvp.13052
5 https://caninearthritis.co.uk/what-is-arthritis/arthritis-the-basics/
6 BEQ : Regulatory approved Biowaiver demonstrating bioequivalence to the reference (Registration procedure parallel to DCP procedure No. IE/V/0775/001-004/DC, GB Vm number: 01656/5031 (20 mg); PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT; https://www.hpra.ie/img/uploaded/swedocuments/Public_AR_VPA10774-075- 003_21082023130723.pdf
More from Krka
19 hours ago